News Agency News Aggregator Journalist/Editor Broking House Others
Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India’s Aurobindo Pharma Ltd as regulators balked, setting back the Swiss drugmaker’s shift to more profitable medicines
AUROBINDO PHARMA: CO AND SANDOZ INC MUTUALLY TERMINATE THE AGREEMENT BETWEEN THEM AS APPROVALS DID NOT COME IN ON TIME
Aurobindo Pharma announces mutual termination of agreement with Sandoz Inc #AurobindoPharma #MutualTermination #Agreement #Sandoz
Aurobindo Pharma and Sandoz Inc mutually terminate the agreement between them as approvals did not come in on time.
Aurobindo - Sandoz deal called off....
Aurobindo Pharma terminates deal with @Novartis to buy US generic and derma business, Sandoz, in a mutual agreement as approval from US Federal Trade Commission for transaction was not obtained within the timeline
Alert: Aurobindo had entered into deal with Sandoz to acquire dermatology and oral businesses in the US for $900 million in September 2018
Novartis announces termination of agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc. Co says decision is taken as approval from US Federal Trade Commission for the transaction was not obtained within anticipated timelines
Negative Development For Aurobindo Pharma @CNBC_Awaaz Novartis reports mutual agreement with Aurobindo to terminate the sale of the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc
AUROPHARMA - Press Release On Mutual Termination Of Definitive Agreement Entered Into For Acquisition Of Certain Commercial Operations #Part1
#Derivative/Future tips (1st April Result 2020) 1. AUROPHARMA FO (Profit Rs 4850/Lot) #Stock Tips, #Derivative #Tips, #F&O Tips, #Future
#Multi/Broker tips (1st April Result 2020) 1. AUROPHARMA FO (Profit Rs 4850/Lot) 2. GRASIM EQ (Profit Rs 11.50/Share) 3. NIFTY Fut (Profit Rs 12375/Lot)